Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
BRISBANE, Calif., Aug. 11, 2017 -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that Cameron Durrant, MD, chairman and CEO, has been named a PharmaVOICE 100 Red Jacket Award honoree as part of the annual PharmaVOICE 100.
The PharmaVOICE 100 Red Jacket Award is a prestigious annual distinction that serves as a ‘hall of fame’ for executives who have been recognized multiple times in the PharmaVOICE 100, the publication’s annual list of inspiring industry leaders. PharmaVOICE 100 Red Jacket Award winners are selected as individuals who have shown a new kind of leadership, such as driving new ways of thinking, acting and leading; creating new opportunities from the ‘impossible’; having persistence of vision; and inspiring leaders for today and tomorrow.
“I am honored and grateful to be inducted into such an influential circle of leaders as the PharmaVOICE 100 Red Jacket Award,” said Dr. Durrant. “Finding new ways forward requires the persistence and resilience to execute and deliver them. This honor reflects the determination and forward-thinking mindset of our talented team at Humanigen, as we continue to execute on our priorities to help neglected and rare disease patients.”
Since January 2016, Dr. Durrant has led the transformation of Humanigen through significant operational, reputational and legal hurdles. Dr. Durrant is a five-time PharmaVOICE 100 honoree. To read the 2017 PharmaVOICE 100 Red Jacket Award profiles, visit www.pharmavoice.com.
About Humanigen
Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit www.humanigen.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
